活动站点
化学
表面等离子共振
噬菌体展示
抗体
变构调节
分子生物学
结合位点
酶
激酶
免疫球蛋白Fab片段
效应器
生物化学
GTP酶
生物
肽序列
基因
肽
纳米颗粒
纳米技术
互补决定区
材料科学
免疫学
作者
Ivo R. Horn,Alfred Wittinghofer,Adriaan P. de Bruïne,Hennie R. Hoogenboom
出处
期刊:FEBS Letters
[Wiley]
日期:1999-12-07
卷期号:463 (1-2): 115-120
被引量:21
标识
DOI:10.1016/s0014-5793(99)01617-8
摘要
The Ras proteins cycle in the cell between an inactive state and an active state. In the active state, Ras signals via the switch I region to effectors like c-Raf kinase, leading to cell growth. Since Ras mutations in cancer are often associated with the presence of permanently active Ras, molecules that prevent downstream signaling may be of interest. Here, we show that by selection on the active conformation of Ras, using a recently described large phage antibody repertoire [de Haard et al. (1999) J. Biol. Chem. 274, 18218-18230], a Fab antibody (Fab H2) was identified that exclusively binds to active Ras, and not to inactive Ras. Using surface plasmon resonance (SPR) analysis, the interaction was demonstrated to be of high affinity (7.2 nM). In addition, the interaction with Ras is specific, since binding to the homologous Rap1A protein in BIAcore analysis is at least three orders of magnitude lower, and undetectable in an enzyme-linked immunosorbent assay. The antibody fragment prevents the binding of active Ras to the immobilized Ras-binding domain of c-Raf kinase (Raf-RBD) at an IC(50) value of 135 nM. This value compares well to the K(D) of active Ras-binding to immobilized Raf-RBD using SPR, suggesting identical binding sites. Like the IgG Y13-259, which does not demonstrate preferential binding to either inactive or active Ras, Fab H2 inhibits intrinsic GTPase activity of Ras in vitro. Mapping studies using SPR analysis demonstrate that the binding sites for the antibodies are non-identical. This antibody could be used for dissecting functional differences between Ras effectors. Due to its specificity for active Ras, Fab H2 may well be more selective than previously used anti-Ras antibodies, and thus could be used for gene therapy of cancer with intracellular antibodies.
科研通智能强力驱动
Strongly Powered by AbleSci AI